What one share of Royalty Pharma holds
We are the largest buyer of biopharmaceutical royalties and a leading funder of innovation across the biopharmaceutical industry. Since our founding in 1996, we have been pioneers in the royalty market, collaborating with innovators from academic institutions, research hospitals and not-for-profits through small and mid-cap biotechnology companies to leading global pharmaceutical companies.
Royalty Pharma’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Sales | $4.54 |
|---|---|
| Profit | $1.87 |
| Cash and investments | $1.82 |
| Debt | $20.14 |
| Book value | $21.99 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2020 | $5.65 | $1.32 | — | — | $0.30 | $26.36 |
| 2021 | $5.52 | $1.49 | — | — | $0.68 | $24.71 |
| 2022 | $5.11 | $0.10 | — | — | $0.76 | $21.75 |
| 2023 | $3.91 | $2.53 | — | — | $0.80 | $22.53 |
| 2024 | $3.81 | $1.91 | — | — | $0.84 | $23.08 |
| 2025 | $4.21 | $1.78 | — | — | — | $22.60 |
Common questions about Royalty Pharma
How much does one share of Royalty Pharma earn?
Over the last 12 months, each share of Royalty Pharma earned $1.87 of profit on $4.54 of sales, keeping about 41¢ of every $1 (profit margin).
Does Royalty Pharma pay a dividend?
Royalty Pharma didn’t pay a dividend over the last 12 months, according to its SEC filings.
What is Royalty Pharma’s book value per share?
Royalty Pharma’s book value is $21.99 per share: what would be left for each share if it sold everything at the values on its books and paid every debt, as of June 30, 2026.
How much cash and debt does each share of Royalty Pharma have?
Each share of Royalty Pharma has $1.82 of cash and investments and $20.14 of debt, as of June 30, 2026.
How has Royalty Pharma’s profit per share changed over time?
Profit per share went from $1.32 in 2020 to $1.78 in 2025, growing about 6.2% a year (adjusted for stock splits).
Has Royalty Pharma bought back shares?
Royalty Pharma’s share count rose about 50% from 2020 to 2025. That dilution means each share owns a smaller slice of the company.
From its SEC filings. For education only, not investment advice. New to these words? See the StockSlicer glossary.